SEOR SBRT‑SG stereotactic body radiation therapy consensus guidelines for non‑spine bone metastasis
-
F. Lopez Campos [1] ; J. Cacicedo [6] ; F. Couñago [2] ; R. García [3] ; O. Leaman Alcibar [4] ; A. Navarro Martin [5] ; H. Pérez Montero [5] ; A. Conde Moreno [7]
-
[1] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[2] Universidad Europea de Madrid
Universidad Europea de Madrid
Madrid, España
-
[3] Hospital Ruber Internacional
Hospital Ruber Internacional
Madrid, España
-
[4] Hospital General Universitario Gregorio Marañón
Hospital General Universitario Gregorio Marañón
Madrid, España
-
[5] Hospital Duran i Reynals
Hospital Duran i Reynals
Barcelona, España
-
[6] Radiation Oncology Department, Osakidetza/Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain
-
[7] Radiation Oncology Department, Hospital Universitario y Politécnico La Fe, Valencia, CEU Cardenal Herrera University, Castellón, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 2, 2022, págs. 215-226
- Idioma: inglés
- Enlaces
-
Resumen
The use of stereotactic body radiation therapy (SBRT) to treat non-spine bone metastases (NSBM) is becoming increasingly common in clinical practice. The clinical advantages of SBRT include good pain control and high local control rates, although only limited data are available. The Spanish Society of Radiation Oncology (SEOR) SBRT group recently convened a task force of experts in the field to address key questions related to SBRT for NSBM, including treatment indications, planning, techniques, and dose fractionation. The task force reviewed the available literature to develop evidence-based recommen- dations for the safe application of NSBM SBRT and to standardize and optimize SBRT processes. The present document provides a comprehensive analysis of the available data, including ongoing clinical trials and controversies, providing clini- cally applicable recommendations
